This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Miyazaki, T. Articles by Kohno, S. Search for Related Content PubMed PubMed Citation Articles by Miyazaki, T. Articles by Kohno, S. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Yeast Infections

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2006, p. 580-586, Vol. 50, No. 2
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.2.580-586.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Fluconazole Treatment Is Effective against a Candida albicans erg3/erg3 Mutant In Vivo Despite In Vitro Resistance

Taiga Miyazaki,^1,2 Yoshitsugu Miyazaki,^1* Koichi Izumikawa,¹ Hiroshi Kakeya,¹ Shunichi Miyakoshi,³ John E. Bennett,² and Shigeru Kohno¹

Second Department of Internal Medicine, Nagasaki University School of Medicine, 1-7-1 Sakamoto, Nagasaki 852-8501,¹ Lead Discovery Research Laboratories, Sankyo Co., Ltd., Tokyo, Japan,³ Clinical Mycology Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland²

Received 13 October 2005/ Returned for modification 7 November 2005/ Accepted 23 November 2005

Candida albicans ERG3 encodes a sterol C5,6-desaturase which is essential for synthesis of ergosterol. Defective sterol C5,6 desaturation has been considered to be one of the azole resistance mechanisms in this species. However, the clinical relevance of this resistance mechanism is still unclear. In this study, we created a C. albicans erg3/erg3 mutant by the "Ura-blaster" method and confirmed the expected azole resistance using standard in vitro testing and the presence of ergosta-7,22-dien-3ß-ol instead of ergosterol. For in vivo studies, a wild-type URA3 was placed back into its native locus in the erg3 homozygote to avoid positional effects on URA3 expression. Defective hyphal formation of the erg3 homozygote was observed not only in vitro but in kidney tissues. A marked attenuation of virulence was shown by the longer survival and the lower kidney burdens of mice inoculated with the reconstituted Ura⁺ erg3 homozygote relative to the control. To assess fluconazole efficacy in a murine model of disseminated candidiasis, inoculum sizes of the control and the erg3 homozygote were chosen which provided a similar organ burden. Under these conditions, fluconazole was highly effective in reducing the organ burden in both groups. This study demonstrates that an ERG3 mutation causing inactivation of sterol C5,6-desaturase cannot confer fluconazole resistance in vivo by itself regardless of resistance measured by standard in vitro testing. The finding questions the clinical significance of this resistance mechanism.

---

* Corresponding author. Mailing address: Second Department of Internal Medicine, Nagasaki University School of Medicine, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan. Phone: 81-95-849-7273. Fax: 81-95-849-7285. E-mail: ym46{at}net.nagasaki-u.ac.jp.

---

Antimicrobial Agents and Chemotherapy, February 2006, p. 580-586, Vol. 50, No. 2
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.2.580-586.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

This article has been cited by other articles:

• Cowen, L. E., Steinbach, W. J. (2008). Stress, Drugs, and Evolution: the Role of Cellular Signaling in Fungal Drug Resistance. Eukaryot Cell 7: 747-764 [Full Text]  
• Cheng, S., Clancy, C. J., Nguyen, K. T., Clapp, W., Nguyen, M. H. (2007). A Candida albicans Petite Mutant Strain with Uncoupled Oxidative Phosphorylation Overexpresses MDR1 and Has Diminished Susceptibility to Fluconazole and Voriconazole. Antimicrob. Agents Chemother. 51: 1855-1858 [Abstract] [Full Text]